{"id":1767,"date":"2017-01-06T12:19:16","date_gmt":"2017-01-06T12:19:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1767"},"modified":"2025-05-19T11:43:52","modified_gmt":"2025-05-19T06:13:52","slug":"nmda-receptor-antagonist-emerging-therapies-in-cns","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns","title":{"rendered":"NMDA Receptor Antagonist: Emerging therapies in CNS"},"content":{"rendered":"<p style=\"text-align: justify;\">Over the last few decades, the N-methyl-D-aspartate receptor (also known as the NMDA receptor or NMDAR) has received much attention due to their role in brain development and function. They are ionotropic receptors found in nerve cells, gets activated by binding of glutamate and glycine. NMDRs are heteromers composed of NR1 and NR2 subunits. NR2 subunits have four subtypes (A-D) in which NR2A and NR2B are predominant. NMDARs are critical to synaptic transmission, synaptic plasticity and memory function. Dysfunction in NMDAR causes several neuropathological and neurodegenerative disorders including schizophrenia, depression, tinnitus, epilepsy, neuropathic pain, Alzheimer\u2019s disease, Huntington\u2019s, Parkinson\u2019s etc.<\/p>\n<p style=\"text-align: justify;\">The excitotoxic NMDA receptor activation causes acute and chronic neurological disorders. This led to the discovery of many potential\u00a0<a href=\"https:\/\/www.delveinsight.com\/report-store\/nmda-receptor-antagonist-pipeline-insight\">clinically relevant therapeutics<\/a> that aims at blocking excessive NMDA activation without interfering normal NMDA functionality required for normal synaptic transmission and plasticity. To date, several drugs has been developed and tested in different clinical studies and few have achieved FDA approval. Ketamine, methadone, memantine, amantadine, and dextromethorphan are the approved NMDAR antagonist. Amongst them, Ketamine is the strong NMDAR antagonist. Despite their clinical success, these drugs pose many side effects including hallucinations, catatonia, ataxia, nightmares, and memory deficits. These drugs are also addictive that makes it difficult to use for anything that requires prolonged dosing.<\/p>\n<p style=\"text-align: justify;\">Over the time, researchers and drug developers are trying to overcome these side effects. Several emerging therapeutics are in late stage development that promise to provide maximum efficacy with minimum side effects. More than 20 companies are developing drug candidates against this potential target. The major players are Johnson &amp; Johnson (esketamine), Auris Medical (Keyzilen), NeuroRx, Inc. (Cyclurad), Avanir Pharmaceuticals (CERC 301), etc., whose drugs are in late stage of clinical development.<\/p>\n<p><em>Jyoti Kumari<br \/>\n<\/em><em>Associate Analyst<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Over the last few decades, the N-methyl-D-aspartate receptor (also known as the NMDA receptor or NMDAR) has received much attention due to their role in brain development and function. They are ionotropic receptors found in nerve cells, gets activated by binding of glutamate and glycine. NMDRs are heteromers composed of NR1 and NR2 subunits. NR2 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1768,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[121,735,634,734,712],"industry":[17225],"therapeutic_areas":[17229],"class_list":["post-1767","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biotechnology","tag-clinical-studies","tag-drug-development","tag-nmda-receptor","tag-pharma-industry","industry-pharmaceutical","therapeutic_areas-central-nervous-system"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NMDA (N-methyl-D-aspartate) Receptor Antagonist For Treatment of CNS<\/title>\n<meta name=\"description\" content=\"The excitotoxic NMDA receptor activation causes acute and chronic neurological disorders. This led to the discovery of many potential\u00a0clinically...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMDA (N-methyl-D-aspartate) Receptor Antagonist For Treatment of CNS\" \/>\n<meta property=\"og:description\" content=\"The excitotoxic NMDA receptor activation causes acute and chronic neurological disorders. This led to the discovery of many potential\u00a0clinically...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-01-06T12:19:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-19T06:13:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/01\/12092242\/NMDAStructure.png\" \/>\n\t<meta property=\"og:image:width\" content=\"991\" \/>\n\t<meta property=\"og:image:height\" content=\"1144\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMDA (N-methyl-D-aspartate) Receptor Antagonist For Treatment of CNS","description":"The excitotoxic NMDA receptor activation causes acute and chronic neurological disorders. This led to the discovery of many potential\u00a0clinically...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns","og_locale":"en_US","og_type":"article","og_title":"NMDA (N-methyl-D-aspartate) Receptor Antagonist For Treatment of CNS","og_description":"The excitotoxic NMDA receptor activation causes acute and chronic neurological disorders. This led to the discovery of many potential\u00a0clinically...","og_url":"https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-01-06T12:19:16+00:00","article_modified_time":"2025-05-19T06:13:52+00:00","og_image":[{"width":991,"height":1144,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/01\/12092242\/NMDAStructure.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns","url":"https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns","name":"NMDA (N-methyl-D-aspartate) Receptor Antagonist For Treatment of CNS","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/01\/12092242\/NMDAStructure.png","datePublished":"2017-01-06T12:19:16+00:00","dateModified":"2025-05-19T06:13:52+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The excitotoxic NMDA receptor activation causes acute and chronic neurological disorders. This led to the discovery of many potential\u00a0clinically...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/nmda-receptor-antagonist-emerging-therapies-in-cns#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/01\/12092242\/NMDAStructure.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/01\/12092242\/NMDAStructure.png","width":991,"height":1144},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/01\/12092242\/NMDAStructure-260x300.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Biotechnology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Clinical Studies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">drug development<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NMDA Receptor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biotechnology<\/span>","<span class=\"advgb-post-tax-term\">Clinical Studies<\/span>","<span class=\"advgb-post-tax-term\">drug development<\/span>","<span class=\"advgb-post-tax-term\">NMDA Receptor<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>"]}},"comment_count":"8","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Jan 6, 2017","modified":"Updated on May 19, 2025"},"absolute_dates_time":{"created":"Posted on Jan 6, 2017 12:19 pm","modified":"Updated on May 19, 2025 11:43 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1767"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1767\/revisions"}],"predecessor-version":[{"id":32227,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1767\/revisions\/32227"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1768"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1767"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1767"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}